Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Levy, Benjamin; Barlesi, Fabrice; Paz-Ares, Luis; Bennouna, Jaafar; Erman, Mustafa; Felip, Enriqueta; Isla, Dolores; Ryun Kim, Hye; Kim, Sang-We; Madelaine, Jeannick; Molinier, Olivier; Özgüroğlu, MUSTAFA; Rodríguez Abreu, Delvys; Adeniji, Abidemi; Lorence, Robert; Voccia, Isabelle; Chisamore, Michael; Riess, Jonathan

doi:10.1016/j.lungcan.2022.01.023

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Levy B., Barlesi F., Paz-Ares L., Bennouna J., Erman M., Felip E., ...More

Lung cancer (Amsterdam, Netherlands), vol.166, pp.107-113, 2022 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 166
Publication Date: 2022
Doi Number: 10.1016/j.lungcan.2022.01.023
Journal Name: Lung cancer (Amsterdam, Netherlands)
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Page Numbers: pp.107-113
Keywords: Carcinoma, Squamous Cell, Afatinib, Pembrolizumab, OPEN-LABEL, DOCETAXEL, TRIALS
Open Archive Collection: AVESIS Open Access Collection
Istanbul University-Cerrahpasa Affiliated: No

Abstract

Introduction: Afatinib and pembrolizumab have separately shown survival benefit in patients with squamous cell carcinoma (SqCC) of the lung, and there is biological rationale for concurrent inhibition of the programmed death ligand-1 and epidermal growth factor receptor (EGFR) pathways in this patient population.